ORMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oramed Pharmaceuticals Inc (ORMP) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, absence of significant trading trends, and no clear technical or options-based signals suggest holding off on investment until stronger catalysts or signals emerge.
The technical indicators show a mixed picture. The MACD is slightly positive but contracting, RSI is neutral, and moving averages are bullish. However, the stock is trading near its resistance level (R1: 3.934), which limits immediate upside potential. The stock has a 30% chance of minor gains in the next week or month, but these are not compelling enough for a long-term investment decision.
NULL identified. No recent news, significant trading trends, or influential figure activity to act as a catalyst.
Additionally, there is no recent congress trading data or analyst upgrades to support a positive outlook.
In Q4 2025, revenue remained stagnant at 0, net income dropped significantly to -$10,009,000 (-198.23% YoY), and EPS fell to 0.24 (-196.00% YoY). Gross margin increased slightly to 0.65, but this is not enough to offset the poor overall financial performance.
No recent analyst rating or price target changes available for ORMP.
